Related Experiment Video

Updated: May 8, 2026

Precision Implementation of Minimal Erythema Dose (MED) Testing to Assess Individual Variation in Human Inflammatory Response
06:31

Precision Implementation of Minimal Erythema Dose (MED) Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

From diagnosis to treatment response: predicting FMF50 response using PREDICT-crFMF and TURPAID scores in children

Eda Nur Dizman1, Feray Kaya1, Elif Kucuk1

  • 1Department of Pediatric Rheumatology, Istanbul Medeniyet University, Istanbul, Turkey.

Clinical Rheumatology
|May 7, 2026
PubMed

Insights

Higher PREDICT-crFMF and TURPAID scores at diagnosis predict poor response to colchicine treatment in children with Familial Mediterranean Fever (FMF). Early assessment can identify patients at risk for treatment resistance.

Area of Science:

  • Pediatric Rheumatology
  • Genetics
  • Clinical Trials

Background:

  • Familial Mediterranean Fever (FMF) is a genetic autoinflammatory disorder.
  • Colchicine is the standard treatment, but some patients exhibit resistance.
  • Predictive scoring systems are needed to identify non-responders early.

Purpose of the Study:

  • To assess the predictive value of TURPAID and PREDICT-crFMF scores for FMF50 response at 6 months in pediatric FMF patients.
  • To examine the association of these scores with disease activity and inflammatory markers.

Main Methods:

  • Retrospective analysis of 168 children newly diagnosed with FMF treated with colchicine for at least 6 months.
  • Evaluation of treatment response using the FMF50 criteria at 6-month follow-up.
  • Statistical analysis of TURPAID and PREDICT-crFMF scores, disease activity indices, and acute-phase reactants.

Main Results:

  • 64.8% of patients achieved FMF50 response.
  • Higher PREDICT-crFMF and TURPAID scores at diagnosis were significant predictors of FMF50 nonresponse (p < 0.001).
  • Both scores demonstrated significant discriminative ability (AUC > 0.67) and correlated with inflammatory markers and disease activity.

Conclusions:

  • The PREDICT-crFMF and TURPAID scores can aid in the early identification of pediatric FMF patients at risk for colchicine resistance.
  • These scores reflect the early inflammatory burden and can guide treatment strategies.
  • This study is the first to jointly evaluate these scores for predicting FMF50 response in children.
Abstract

Keywords:
Colchicine resistanceFamilial Mediterranean FeverPediatricsPredictive scoreTreatment

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.